Please ensure Javascript is enabled for purposes of website accessibility

Intrexon Corp. Shares Soar Again on Zika Virus Concerns

By Sean Williams - Feb 4, 2016 at 4:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Zika virus continues to spread North, prompting state of emergency declarations in five Florida counties.

What: Shares of Intrexon (PGEN 4.76%), a developer of gene-based medicines, scorched higher by as much as 15% during Thursday's trading session thanks to growing fears over the spread of the Zika virus.

So what: The Zika virus is an arbovirus, meaning it's spread from insect to human, and not from human to human. The culprit is the Aedes Aegypti mosquito, which has been wreaking havoc in Brazil, and is now working its way up into Central and North America. The virus itself only winds up making one-in-five adults it infects ill, and the resulting symptoms if you are one of those five are usually mild (joint pain, fever, and rash).

The concern is the more than 20-fold increase in microcephaly cases in Brazil that happens to coincide with the spread of the Zika virus. Microcephaly is a rare condition where the brain fails to fully develop, resulting in a smaller head.

More infants than normal have presented with this condition in Brazil in recent months, which was the impetus behind Brazil's President, Dilma Rousseff, calling the disease a "real threat." Additional testing is underway to confirm if there's a link, but the Centers for Disease Control and Prevention has advised pregnant women not to travel to more than a dozen Zika virus hot zones.

Today, we also witnessed Florida's governor declaring a state of emergency in five counties where the Zika virus has been diagnosed.

Image source: Centers for Disease Control and Prevention. 

Now what: The reason Intrexon shares are shooting through the roof is due to its purchase last summer of Oxitec, which is a company working to eradicate a number of global diseases -- and one just so happens to be the Zika virus. Oxitec is working on modifying the genetic make-up of male mosquitos.

The idea here is that these mosquitos would pass along a gene that would cause future generations to die young before reaching the reproductive age. If successful, Oxitec's solution would dramatically decrease the Zika virus-carrying mosquito population. These genetically modified male mosquitos are being tested in Brazil, Panama, and the Cayman Islands at the moment.

While I can certainly see why investors are so excited, it's also important to keep things in perspective. To begin with, pandemic and epidemic solutions aren't always surefire winners for developing companies. We witnessed drug developers working on an Ebola cure shoot into the stratosphere, only to have cross-border cooperation work to contain the disease. We could see the same thing happen with the Zika virus.

By a similar token, we're also talking about a disease that's far less deadly than past pandemics. Ebola had a mortality rate of roughly 40%. By contrast, there have been just a handful of confirmed cases of microcephaly in Brazil with a Zika infection (and microcephaly isn't necessarily a death sentence). In other words, investors could be going a bit overboard with this move higher.

I would personally suggest paying attention to Intrexon's partnership with Ziopharm Oncology for CAR-T cancer therapies, because that's where the real value of Intrexon likely lies.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Precigen, Inc. Stock Quote
Precigen, Inc.
$2.42 (4.76%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.